| scholarly article | Q13442814 |
| P50 | author | Alain Bron | Q57571450 |
| Catherine Creuzot-Garcher | Q64866954 | ||
| P2093 | author name string | Morgane Straub | |
| Aurore Muselier-Mathieu | |||
| P2860 | cites work | Topical ciclosporin in the treatment of ocular surface disorders | Q24670344 |
| Tear film MMP accumulation and corneal disease | Q28346325 | ||
| The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca | Q33218520 | ||
| Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group | Q34523084 | ||
| Management of dry eye disease | Q34775502 | ||
| Dry eye diagnosis and management in 2004. | Q35825728 | ||
| Ocular safety of cationic emulsion of cyclosporine in an in vitro corneal wound-healing model and an acute in vivo rabbit model | Q36182937 | ||
| Dysfunctional tear syndrome: a Delphi approach to treatment recommendations | Q36653052 | ||
| Prevalence, burden, and pharmacoeconomics of dry eye disease. | Q37152821 | ||
| CD8⁺ cells regulate the T helper-17 response in an experimental murine model of Sjögren syndrome | Q37407580 | ||
| Clinical Review: Topical Ophthalmic Use of Cyclosporin A | Q37782084 | ||
| Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease. | Q38171801 | ||
| Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. | Q40948258 | ||
| Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group | Q41730611 | ||
| Topical cyclosporine 0.05% for the prevention of dry eye disease progression | Q43087530 | ||
| Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy | Q43228564 | ||
| Antiinflammatory therapy for dry eye. | Q44763839 | ||
| Incidence of dry eye in an older population | Q44790453 | ||
| The lack of association between signs and symptoms in patients with dry eye disease | Q45122466 | ||
| Pharmacologic treatments for dry eye: a worthwhile investment? | Q46338656 | ||
| Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis | Q46965028 | ||
| Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. | Q48648762 | ||
| Evaluation of the effect of topical cyclosporine A with impression cytology in dry eye patients. | Q51583304 | ||
| Reversibility of dry eye deceleration after topical cyclosporine 0.05% withdrawal. | Q53143850 | ||
| Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes | Q73180482 | ||
| Reliability and validity of the Ocular Surface Disease Index | Q73801624 | ||
| Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion | Q74120740 | ||
| Self-reported compliance with topical cyclosporine emulsion 0.05% and onset of the effects of increased tear production as assessed through patient surveys | Q79526746 | ||
| Design and conduct of clinical trials: report of the Clinical Trials Subcommittee of the International Dry Eye WorkShop (2007) | Q80347916 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cyclosporine | Q367700 |
| eye disease | Q3041498 | ||
| P304 | page(s) | 1547-1550 | |
| P577 | publication date | 2016-01-28 | |
| P1433 | published in | British Journal of Ophthalmology | Q13443571 |
| P1476 | title | Long-term outcome after topical ciclosporin in severe dry eye disease with a 10-year follow-up | |
| P478 | volume | 100 |
| Q92824372 | Dry Eye Disease: A Review of Epidemiology in Taiwan, and its Clinical Treatment and Merits |
| Q50025206 | Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program. |
| Q50039889 | [Novel current and future therapy options for treatment of dry eye disease]. |
Search more.